Explainable artificial intelligence (XAI) in schizophrenia: enhancing transparency in clinical decision-making.

Authors

Kshitij Srivastava, Ruby Srivastava

Published in

Frontiers in systems biology. Volume 6. Pages 1898853. Epub Sep 28, 2026.

Abstract

Schizophrenia is a chronic and severe psychiatric disorder affecting nearly 1% of the global population, characterized by positive symptoms such as hallucinations and delusions, negative symptoms including avolition and affective flattening, and cognitive impairments that compromise social and occupational functioning. Despite advances in psychiatry, diagnosis remains largely symptom-based, relying on criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-11), highlighting the need for objective biomarkers and improved clinical decision support. Neuroimaging modalities, including structural and functional magnetic resonance imaging (MRI/fMRI), diffusion tensor imaging (DTI), positron emission tomography (PET), as well as electrophysiological techniques such as electroencephalography (EEG) and magnetoencephalography (MEG), have revealed abnormalities in brain connectivity, dopaminergic signaling, sensory processing, and network dysfunction associated with schizophrenia. Recent advances in artificial intelligence (AI), particularly machine learning (ML), have enabled prediction of diagnosis, treatment response, and relapse risk using multimodal clinical, neuroimaging, and genetic data. However, the "black-box" nature of many AI models limits transparency, interpretability, and clinician trust, restricting translation into practice. Explainable artificial intelligence (XAI) addresses these challenges by providing interpretable, transparent, and clinically accountable models that support decision-making while preserving ethical and regulatory standards. By integrating explainable models with multimodal data, clinicians can use them as an adjunct for precision psychiatry, facilitating biomarker discovery, personalized treatment strategies, and trustworthy, actionable decisions, ultimately enhancing transparency and improving outcomes in schizophrenia care.

PMID:
42865580
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.